Bruker (BRKR) Q2 Revenue Slips 0.4%

(NASDAQ:BRKR), a global provider of scientific instruments and analytical solutions, reported earnings for Q2 2025 on August 4, 2025. GAAP revenue was $797.4 million, below the analyst consensus estimate of $810.1 million. Non-GAAP earnings per share (EPS) were $0.32, also falling short of the $0.41 expected by analysts. Compared to the prior year, GAAP revenue slipped 0.4%. while non-GAAP EPS declined 38.5%. Management described the quarter as challenging, citing lower demand in key U.S. academic and biopharma markets, persistent tariff and currency headwinds, and margin compression. In response, the company revised its full-year guidance downward and announced an expanded cost savings initiative, reflecting a cautious outlook for the remainder of the year.

Source: Analyst estimates for the quarter provided by FactSet.

Bruker designs and manufactures advanced scientific instruments for research, diagnostics, and industrial applications. Its main product lines include nuclear magnetic resonance (NMR) systems, mass spectrometers, and X-ray technologies. These tools help scientists study molecules, cells, and materials at very small scales.

Continue reading

Source Fool.com